Prediction of progression in pTa and pTl bladder carcinomas with p53, p16 and pRb

British Journal of Cancer

Volumn 91, Issue 3, 2004, Pages 552-557

  Hitchings, A W ^a   Kumar, M ^a   Jordan, S ^a   Nargund, V ^a   Martin, J ^a   Berney, D M ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Immunohistochemistry; Molecular markers; Prognosis; Transitional cell carcinoma

Indexed keywords

PARAFFIN; PROTEIN P16; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETINOBLASTOMA PROTEIN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 4143081719     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601954     Document Type: Article

References (27)

1. Abdel-Fattah R, Challen C, Griffiths TR, Robinson MC, Neal DE, Lunec J (1998) Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 77: 2230-2238
2. Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czerniak B (1999) Levels of retinoblastoma protein expression correlates with p16 (MTS-1/ INK4A/CDKN2) status in bladder cancer. Oncogene 18: 1197-1203
3. Cordon-Cardo C, Zhang Z-F, Dalbagni G, Drobnjak M, Charytonowicz E, Hu S-X, Xu H-J, Reuter VE, Benedict WF (1997) Cooperative effects of p53 and pRB alterations in primary superficial bladder tumours. Cancer Res 57: 1217-1221
4. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, Reuter VE, Pellicer A (1994) p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 56: 347-353
5. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi S-R, Tran Q-C, Hu S-X, Xu H-J, Groshen S, Taylor CR, Skinner DG, Benedict WF (1998) Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 58: 1090-1094
6. Esrig D, Spruck III CH, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RJ (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumour grade, and stage in bladder cancer. Am J Pathol 143: 1389-1397
7. Finlay CA, Hinds PW, Tan TH (1988) Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539
8. Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR (1994) Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer 69: 26-31
9. Friedrich MG, Blind C, Milde-Langosch K, Erbersdobier A, Conrad S, Löning T, Hammerer A, Huland H (2001) Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumour recurrence. Eur Urol 40: 518-524
10. INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 55: 6006-6011
11. Gorgoulis VG, Zacharatos P, Kotsinas A, Liloglou T, Kyroudi A, Veslemes M, Rassidakis A, Halazonetis TD, Field JK, Kittas C (1998) Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas (NSCLCs): relationship with p53 and MDM2 protein expression. Am J Pathol 153: 1749-1765
12. Grossman HB, Liebert M, Antelo M, Dinney CPN, Hu S-X, Palmer JL, Benedict WF (1998) p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4: 829-834
13. Knowles M (2001) What we can do now: molecular pathology of bladder cancer. J Clin Pathol 54: 215-221
14. Korkolopoulou P, Christodoulou P, Lazaris A, Thomas-Tsagli E, Lapralos P, Papanikolaou A, Kalliteraki I, Davaris P (2000) Prognostic implications of aberrations in p16/pRb pathway in urothelial bladder carcinomas: a multivariate analysis including p53 expression and proliferation markers. Eur Urol 39: 167-177
15. Lacombe L, Dalbagni G, Zhang Z-F, Cordon-Cardo C, Fair WR, Herr HW, Reuter VE (1996) Overexpression of p53 protein in a high risk population of patients with superficial bladder cancer before and after bacillus Calmette - Guérin therapy: correlation to clinical outcome. J Clin Oncol 14: 2646-2652
16. Masters JRW, Vani UD, Grigor KM, Griffiths GO, Crook A, Parmar MKB, Knowles MA, with the MRC Superficial Bladder Cancer Group Mitomycin-C Trial Collaborators (2003) Can p53 staining be used to identify patients with aggressive superficial bladder cancer? J Pathol 200: 74-81
17. McShane LM, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Fradet Y, Grossman HB, Peng A, Taube SE, Waldman FM, the National Cancer Institute Bladder Tumour Marker Network (2000) Reproducibility of p53 immunohistochemistry in bladder tumors. Clin Cancer Res 6: 1854-1864
18. Mostofi FH, Sobin LH, Torloni H (1973) International Classification of Tumours, (10th edn) World Health Organisation: Geneva
19. Neihans GA, Kratzke RA, Froberg MK, Aeppli DM, Nguyen PL, Geradts J (1999) G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder. Br J Cancer 80: 1175-1184
20. Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, Meyer F, Fradet Y, Cordon-Cardo C (1999) Deletions of the INK4A gene in superficial bladder tumours, association with recurrence. Am J Pathol 155: 105-113
21. Pfister C, Moore L, Allard P, Larue H, Lacombe L, Tetu B, Meyer F, Fradet Y (1999) Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumour recurrence. Clin Cancer Res 5: 4079-4084
22. Santos LL, Amaro T, Pereira SA, Lameiras CR, Lopes P, Bento MJ, Oliveira J, Criado B, Lopes CS (2003) Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. Eur J Surg Oncol 29: 74-80
23. Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, Tan HK, Jonas U (1995) p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 71: 201-205
24. Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 59: 3245-3250
25. Sobin LH, Wittekind CH (2002) TNM Classification of Malignant Tumours, (6th edn) John Wiley & Sons: Chichester
26. Yang C-C, Chu K-C, Chen H-Y, Chen W-C (2002) Expression of p16 and Cyclin D1 in bladder cancer and correlation in cancer progression. Urol Int 69: 190-194
27. Zhang X, Xu H-J, Murakami Y, Sachse R, Yashima K, Hirohashi S, Hu S-X, Benedict WF, Sekiya T (1994) Deletions of chromosome 13q mutations in retinoblastoma 1 and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 54: 4177-4182